T-cell receptor γδ T-cell leukemia with the morphology of T-cell prolymphocytic leukemia and a postthymic immunophenotype

2001 ◽  
Vol 80 (12) ◽  
pp. 749-751 ◽  
Author(s):  
T. Sugimoto ◽  
S. Imoto ◽  
Y. Matsuo ◽  
K. Kojima ◽  
M. Yasukawa ◽  
...  
Retrovirology ◽  
2015 ◽  
Vol 12 (S1) ◽  
Author(s):  
Aileen G Rowan ◽  
Paul Fields ◽  
Graham P Taylor ◽  
Charles RM Bangham

2016 ◽  
Vol 12 (11) ◽  
pp. e1006030 ◽  
Author(s):  
Aileen G. Rowan ◽  
Aviva Witkover ◽  
Anat Melamed ◽  
Yuetsu Tanaka ◽  
Lucy B. M. Cook ◽  
...  

Blood ◽  
1993 ◽  
Vol 81 (4) ◽  
pp. 1032-1039 ◽  
Author(s):  
H Suzushima ◽  
N Asou ◽  
S Nishimura ◽  
K Nishikawa ◽  
JX Wang ◽  
...  

Abstract We present four patients with adult T-cell leukemia (ATL) derived from a novel T-cell subset (CD4-, CD8- [double-negative, DN], T-cell receptor [TCR] alpha beta+). In the ATL cells of these patients, neither gene nor surface expression of CD4 and CD8 antigens was detected. Clinical and laboratory data showed no difference between DN- ATL and CD4+ATL patients. In contrast to typical CD4+ATL cells, DN-ATL cells were shown to express the protein and messenger RNA (mRNA) for S100 beta in immunocytochemical assay and the reverse-transcription polymerase chain reaction assay. The mean fluorescence intensity of the TCR/CD3 complex was extremely low in all four DN-ATL patients as well as in typical CD4+ ATL. All four patients had TCR beta and gamma chain gene rearrangements, with deletion of TCR delta chain gene and mRNA expression for TCR alpha, beta, and CD3 delta but not for TCR gamma and delta chain genes. Thus, CD4- CD8- TCR alpha beta T cells are also a target for human T-cell lymphotrophic virus type I-induced leukemogenesis. In addition, expression of the TCR alpha beta/CD3 complex on the DN-ATL cells was further diminished by the addition of anti-CD3 or anti-TCR alpha beta monoclonal antibody. These results suggest that the decreased expression of the TCR alpha beta/CD3 complex by ATL cells plays a key role in the development of ATL, irrespective of CD4 expression.


2017 ◽  
Vol 7 (3) ◽  
pp. e1405204 ◽  
Author(s):  
Takero Shindo ◽  
Kazutaka Kitaura ◽  
Hiroshi Ureshino ◽  
Kazuharu Kamachi ◽  
Masaharu Miyahara ◽  
...  

1990 ◽  
Vol 8 (2) ◽  
pp. 111-118 ◽  
Author(s):  
K. Ohshima ◽  
T. Yoshida ◽  
M. Kikuchi ◽  
Y. Masuda ◽  
N. Kimura ◽  
...  

2021 ◽  
Vol 11 ◽  
Author(s):  
Till Braun ◽  
Annika Dechow ◽  
Gregor Friedrich ◽  
Michael Seifert ◽  
Johanna Stachelscheid ◽  
...  

T-cell prolymphocytic leukemia (T-PLL) is the most common mature T-cell leukemia. It is a typically aggressively growing and chemotherapy-resistant malignancy with a poor prognosis. T-PLL cells resemble activated, post-thymic T-lymphocytes with memory-type effector functions. Constitutive transcriptional activation of genes of the T-cell leukemia 1 (TCL1) family based on genomic inversions/translocations is recognized as a key event in T-PLL’s pathogenesis. TCL1’s multiple effector pathways include the enhancement of T-cell receptor (TCR) signals. New molecular dependencies around responses to DNA damage, including repair and apoptosis regulation, as well as alterations of cytokine and non-TCR activation signaling were identified as perturbed hallmark pathways within the past years. We currently witness these vulnerabilities to be interrogated in first pre-clinical concepts and initial clinical testing in relapsed/refractory T-PLL patients. We summarize here the current knowledge on the molecular understanding of T-PLL’s pathobiology and critically assess the true translational progress around this to help appraisal by caregivers and patients. Overall, the contemporary concepts on T-PLL’s pathobiology are condensed in a comprehensive mechanistic disease model and promising interventional strategies derived from it are highlighted.


Sign in / Sign up

Export Citation Format

Share Document